Evidence map›Paper›PMID 26189689›Full record

ArticleEuropean urology2016

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

Piet Ost, Barbara Alicja Jereczek-Fossa, Nicholas Van As, Thomas Zilli, Alexander Muacevic, Kenneth Olivier, Daniel Henderson, Franco Casamassima, Roberto Orecchia, Alessia Surgo and 4 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 3 pooled it
28.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 3 syntheses or guidelines pooled it, 287 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Stereotactic body radiation therapy (SBRT) for spinal metastases: 12 years of a single center experience.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  17. Lesion Dosimetry for [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  18. Article
  19. Review
  20. Review

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 5 countries.

Piet OstDepartment of Radiotherapy, Ghent University Hospital, Belgium. Electronic address: piet.ost@ugent.be.
Barbara Alicja Jereczek-FossaUniversity of Milan and European Institute of Oncology, Milan Italy.
Nicholas Van AsDepartment of Radiotherapy Royal Marsden NHS Foundation Trust, London, UK.
Thomas ZilliDepartment of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.
Alexander MuacevicCyberknife Center Munich Grosshadern, Munich, Germany.
Kenneth OlivierDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Daniel HendersonDepartment of Radiotherapy Royal Marsden NHS Foundation Trust, London, UK.
Franco CasamassimaEcomedica Radioterapia, Empoli, Italy.
Roberto OrecchiaUniversity of Milan and European Institute of Oncology, Milan Italy.
Alessia SurgoUniversity of Milan and European Institute of Oncology, Milan Italy.
Lindsay BrownDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Alison TreeDepartment of Radiotherapy Royal Marsden NHS Foundation Trust, London, UK.
Raymond MiralbellDepartment of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.
Gert De MeerleerDepartment of Radiotherapy, Ghent University Hospital, Belgium.
Royal Marsden NHS Foundation Trust · GBGhent University Hospital · BEMayo Clinic in Arizona · USUniversity Hospital of Geneva · CHUniversity of Milan · ITAzienda Unità Sanitaria Locale 11 di Empoli · ITEuropean Institute of Oncology · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe literature on metastasis-directed therapy for oligometastatic prostate cancer (PCa) recurrence consists of small heterogeneous studies. This study aimed to reduce the heterogeneity by pooling individual patient data from different institutions treating oligometastatic PCa recurrence with stereotactic body radiotherapy (SBRT). We focussed on patients who were treatment naive, with the aim of determining if SBRT could delay disease progression. We included patients with three or fewer metastases. The Kaplan-Meier method was used to estimate distant progression-free survival (DPFS) and local progression-free survival (LPFS). Toxicity was scored using the Common Terminology Criteria for Adverse Events. In total, 163 metastases were treated in 119 patients. The median DPFS was 21 mo (95% confidence interval, 15-26 mo). A lower radiotherapy dose predicted a higher local recurrence rate with a 3-yr LPFS of 79% for patients treated with a biologically effective dose ≤100Gy versus 99% for patients treated with >100Gy (p=0.01). Seventeen patients (14%) developed toxicity classified as grade 1, and three patients (3%) developed grade 2 toxicity. No grade ≥3 toxicity occurred. These results should serve as a benchmark for future prospective trials. PATIENT SUMMARY: This multi-institutional study pools all of the available data on the use of stereotactic body radiotherapy for limited prostate cancer metastases. We concluded that this approach is safe and associated with a prolonged treatment progression-free survival.

Indexed as

RadiosurgeryAbdominal NeoplasmsAgedAndrogen AntagonistsAntineoplastic AgentsBone NeoplasmsDisease-Free SurvivalHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedProstatic NeoplasmsRadiotherapy DosageRetrospective StudiesSurvival RateAndrogen AntagonistsAntineoplastic AgentsNeoplasm metastasisNeoplasm recurrenceOligometastasisProstatic neoplasmsRadiosurgeryStereotactic body radiotherapy

Identifiers

PMID26189689
OpenAlexW2148867458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.